[Clostridioides difficile infection: Current perspectives on diagnosis and therapy]

Area of Science:

• Infectious Diseases
• Microbiology
• Gastroenterology

Background:

• Clostridioides difficile is an opportunistic pathogen causing healthcare-associated infections due to microbiota disruption, often from antibiotics.
• Increasing community-acquired C. difficile infections highlight the need for improved antibiotic stewardship and infection control.
• Disease pathogenesis involves toxins A and B, leading to symptoms from diarrhea to colitis; colonization alone does not require treatment.

Purpose of the Study:

• To review the epidemiology, pathogenesis, diagnosis, and management of Clostridioides difficile infections.
• To discuss current treatment recommendations, emphasizing fidaxomicin and oral vancomycin.
• To highlight the challenges of recurrence and evolving therapeutic strategies.

Main Methods:

• Literature review of Clostridioides difficile infection epidemiology, pathogenesis, and treatment guidelines.
• Analysis of current therapeutic shifts, including fidaxomicin, oral vancomycin, fecal microbiota transplant, and monoclonal antibodies.
• Consideration of regional practices, such as the use of oral vancomycin capsules in the Czech Republic.

Main Results:

• Clostridioides difficile infection incidence reflects antibiotic policies and infection control rigor, with substantial mortality, especially in vulnerable populations.
• Fidaxomicin is recommended for initial episodes due to a lower recurrence risk compared to oral vancomycin.
• Recurrent infections necessitate individualized approaches, potentially including fecal microbiota transplant or monoclonal antibodies.

Conclusions:

• Rational antibiotic policies and hygiene are crucial for preventing Clostridioides difficile infections.
• Treatment strategies have evolved, favoring fidaxomicin for initial episodes to minimize recurrence.
• Management of recurrent C. difficile infection requires personalized strategies, reflecting advances in therapeutic options.